JP2000516585A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516585A5
JP2000516585A5 JP1998508217A JP50821798A JP2000516585A5 JP 2000516585 A5 JP2000516585 A5 JP 2000516585A5 JP 1998508217 A JP1998508217 A JP 1998508217A JP 50821798 A JP50821798 A JP 50821798A JP 2000516585 A5 JP2000516585 A5 JP 2000516585A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998508217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516585A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/013882 external-priority patent/WO1998005323A2/en
Publication of JP2000516585A publication Critical patent/JP2000516585A/ja
Publication of JP2000516585A5 publication Critical patent/JP2000516585A5/ja
Pending legal-status Critical Current

Links

JP10508217A 1996-08-02 1997-08-01 血管新生阻害物質による雌生殖系の調節方法 Pending JP2000516585A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2338596P 1996-08-02 1996-08-02
US60/023,385 1996-08-02
PCT/US1997/013882 WO1998005323A2 (en) 1996-08-02 1997-08-01 Method of regulating the female reproductive system through angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
JP2000516585A JP2000516585A (ja) 2000-12-12
JP2000516585A5 true JP2000516585A5 (enExample) 2005-04-07

Family

ID=21814780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10508217A Pending JP2000516585A (ja) 1996-08-02 1997-08-01 血管新生阻害物質による雌生殖系の調節方法

Country Status (6)

Country Link
US (3) US6017949A (enExample)
EP (1) EP0957910A2 (enExample)
JP (1) JP2000516585A (enExample)
AU (2) AU3968597A (enExample)
CA (1) CA2262535A1 (enExample)
WO (2) WO1998005293A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183378B1 (pl) * 1995-03-27 2002-06-28 Assist Publ Hopitaux De Paris Zastosowanie fumagilolu i jego pochodnych do wytwarzania jelitowych środków przeciwinfekcyjnych
US6440445B1 (en) * 1996-09-30 2002-08-27 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
JP2002502814A (ja) * 1997-10-31 2002-01-29 チルドレンズ・メディカル・センター・コーポレイション 血管化した正常組織の大きさおよび増殖の調節のための方法
EP1119371B1 (en) * 1998-10-09 2010-11-24 Vegenics Limited Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
US7141607B1 (en) * 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US20060234925A1 (en) * 2002-09-04 2006-10-19 Kazuhiko Imakawa Embryo implantation inhibitor
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
AU2004255366B2 (en) * 2003-07-14 2009-06-25 Fusion Sport International Pty Ltd Sports training and testing methods, apparatus and system
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
WO2005021756A1 (en) * 2003-08-29 2005-03-10 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
WO2009139915A2 (en) 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
AU2009270799B2 (en) * 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010012002A1 (en) * 2008-07-25 2010-01-28 Saryna Medical Corporation Methods and systems for genetic analysis of fetal nucleated red blood cells
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
EP2521719B1 (en) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
RU2427325C1 (ru) * 2010-01-29 2011-08-27 Государственное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО АГМА Росздрава) Способ оценки эффективности лечения хронической плацентарной недостаточности в эксперименте
US8774488B2 (en) 2010-03-11 2014-07-08 Cellscape Corporation Method and device for identification of nucleated red blood cells from a maternal blood sample
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
CN103079567A (zh) 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
MX2013005989A (es) 2010-11-29 2013-08-21 Zafgen Inc Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
WO2012154678A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic sulfonamide compounds and methods of making and using same
CA2835209A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
MX345535B (es) 2011-05-06 2017-02-03 Zafgen Inc Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
CA2872649A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6-o-(4-dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
KR20150016534A (ko) 2012-05-09 2015-02-12 자프겐 인크. 푸마지롤형 화합물 및 이의 제조 및 사용 방법
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
WO2014071369A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK168876B1 (da) * 1982-12-20 1994-07-04 Harvard College Middel, der kan administreres oralt eller subcutant, til inhibering af angiogenese hos pattedyr samt fremgangsmåde til fremstilling af et sådant middel
DE3344797A1 (de) * 1983-12-10 1985-06-20 Th. Kieserling & Albrecht Gmbh & Co, 5650 Solingen Transportvorrichtung fuer felgenrohlinge
US4599331A (en) * 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
DE68915900T2 (de) * 1988-09-01 1994-11-24 Childrens Medical Center Angiogenese hemmendes Mittel.
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
CA2081205C (en) * 1990-06-11 2001-02-27 John W. Wilks Steroids which inhibit angiogenesis
FR2672801B1 (fr) * 1991-02-14 1995-03-03 Sanofi Sa Utilisation de derives de tetrahydrothienopyridine comme inhibiteurs de l'angiogenese.
GB9225475D0 (en) * 1992-12-05 1993-01-27 Imp Cancer Res Tech Compounds to combat angiogenesis
DK0690720T3 (da) * 1993-03-12 2001-08-27 Xoma Technology Ltd Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter
DE69417169T2 (de) * 1993-09-24 1999-07-22 Takeda Chemical Industries, Ltd., Osaka Antineoplastische pharmazeutische Zusammensetzung enthaltend ein Fumagillolderivat und einen Platinkomplex
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001506156A5 (enExample)
JP2001527708A5 (enExample)
JP2000513608A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000508206A5 (enExample)
JP2001501409A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000500874A5 (enExample)
JP2000511416A5 (enExample)
JP2000512107A5 (enExample)
JP2000502425A5 (enExample)
JP2000515995A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000516585A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000503849A5 (enExample)
JP2000501744A5 (enExample)
JP2001502673A5 (enExample)